| |
| The United States: Revlimid (lenalidomide) - Ongoing safety review: possible increased risk of developing new malignancies (English Only) |
| |
FDA updated the public about an ongoing safety review of Revlimid (lenalidomide) and a possible increased risk of developing new malignancies. According to results of controlled clinical trials conducted inside and outside the United States, it was found that patients treated with Revlimid (lenalidomide) may be at an increased risk of developing new types of cancer compared to patients who did not take the drug.
Currently, FDA believes the benefits of Revlimid continue to outweigh the potential risks. Patients should continue to follow the advice of their healthcare provider. FDA is reviewing all available information on this potential risk and will communicate any new recommendations once it has completed its review.
Please refer to the following website in FDA for details:
http://www.fda.gov/Drugs/DrugSafety/ucm250575.htm
In Hong Kong, four registered pharmaceutical products, namely Revlimid Cap 5mg, Revlimid Cap 10mg, Revlimid Cap 15mg, Revlimid Cap 25mg, contain lenalidomide. All these products are registered by a local company, Celgene Ltd and are prescription medicines. Department of Health will keep vigilance against any new safety information related to the drugs. Letter to inform healthcare professionals will be issued.
Ends/Saturday, April 9, 2011
Issued at HKT 12:30
|
| |
|
